Fiche centre
Boston Center for Memory
Newton — United States
Essais liés7clinical trials
VilleNewtonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06937229
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Donanemab | Alzheimer | Phase 3 | NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06937229 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | RECRUITING |
| Spectris™ AD - Active | Alzheimer | Non applicable | NCT05637801 | A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) | COMPLETED |
| Trontinemab | Alzheimer | Phase 3 | NCT07717411 | PrevenTRON — A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07169578 | TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Xanomeline/Trospium Chloride Capsule | Alzheimer | Phase 3 | NCT07011732 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | RECRUITING |